2025 ESMO SARCOMA AND RARE CANCERS

Annual Congress

ADVANCING SALIVARY GLAND CANCER RESEARCH: A MULTIDISCIPLINARY APPROACH TO ADDRESSING THE UNMET CLINICAL NEED

Dr Robert Metcalf

Consistant Medical Oncologist, The Christie NHS Foundation Trust, Manchester, UK Honorary Reader, The University of Manchester, Manchester, UK Co-Founder, Salivary Gland Cancer UK (Registered Charity) Co-Chair Salivary Gland Cancer UK Research Working Group

On behalf of SGC UK RWG Members: I Boon, L Bingle, S Dobbs, S Garikpati, M Ho, W Ince, P Jimenez, A Khurram, E Kinloch, N Mani, J McCaul, A Nelson, C Schilling, R Newlands, S Rack, R Rieu, N Spardy Burr, N Stobbs, and S Winter





DECLARATION OF INTERESTS

Robert Metcalf

Speaker, consultancy or advisory roles: Avacta Life Sciences, Rgenta, Regeneron, Sanofi

Non-financial role as co-founder of Salivary Gland Cancer UK (Registered Charity)



Dr Robert Metcalf MB ChB PhD MRCP

BACKGROUND

Unmet need

Salivary Gland Cancer (SGC) represents a significant area of unmet clinical need, with challenges throughout diagnosis, treatment and long-term survival.

Many of these are shared across most rare cancers.



Salivary tumours are most frequently benign

- Maintaining skills required for histopathology is particular challenge (>20 histologies)

Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

BACKGROUND

Unmet need

As a rare and diverse set of cancers, SGC necessitates a multi-institutional, multidisciplinary approach to effectively address the gaps in research and clinical care.



2025 ESMO SARCOMA AND RARE CANCERS

Dr Robert Metcalf MB ChB PhD MRCP

Origin following closure of NCRI (UK National Cancer Research Institute)

The NCRI was established in 2001 and closed in 2023

NCRI **purpose** was to drive **collaboration** between organisations that fund cancer research.

- Collaborating with public funders, charities and industry to shape a cohesive research system
- Sharing information and insight to build best practice and accelerate action
- Convening the best brains in the UK to collaborate on cross-cutting and cutting-edge clinical trials
- Developing world-leading expertise in patient advocate involvement
- Growing a research-ready cancer workforce of the future at scale and speed.



Partners in cancer research

CLOSED 2023

Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

BACKGROUND

Unmet need

The SGC UK Research Working Group (RWG) was formed in 2024

- Transferred in the leadership of the NCRI Salivary Cancer Research Working Group
- . Consumer co-produced
- . Co-chaired by two salivary clinicians and a patient advocate
- Actively sought out and brought together leaders within the field
- . >30 active contributors

Relevant clinical specialties (from pathology through to late effects) Patient advocates

Industry

Charity

International

- Overcoming inter-disciplinary, inter-institutional and international barriers
- Driving collaboration and progress in rare cancers



Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

Prioritising Research Workstreams

Bringing together experts from all relevant specialties to collaborate and set research objectives aimed at improving patient outcomes.



2024

March 2024 In-person meeting to discuss research activities

May 2024 Online voting process to rank research priorities

July 2024 Established 4 workstreams from top four priorities

October 2024 In person meeting to discuss and refine 4 workstreams

Q1 2025 Online meeting to agree workstream deliverables

2025

Q2 2025 In-person meeting to update group

2025 ESMO SARCOMA AND RARE CANCERS

Dr Robert Metcalf MB ChB PhD MRCP

Prioritising Research Wokstreams

1: Collating and reviewing existing national/international SGC guidelines to identify areas of consensus and gaps.

Context/Challenges:

- Current guidelines
 - Royal College of Pathologists (2024)
 - HN Cancer UK Guidelines
 - ESMO 2022
 - ASCO 2022
 - NCCN 2024
 - German Guidelines AWMF-S3

Year 1 deliverables under consideration:

- Perform and publish systematic review of existing guidelines
- Identify and publish consensus on areas of agreement
- Use areas of agreement to benchmark for audit
- Use areas of divergence to support study development

Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

Prioritising Research Wokstreams

2: Investigating the variation in histopathology reporting across UK centres, with a view to collecting data to inform development of larger studies.

Context/Challenges:

- Variable histopathology reporting between centres
- Unclear of optimum number of cases per year to maintain skills
- Informal support/second opinion networks

Year 1 deliverables under consideration:

- Review and publish existing UK pathology databases for change in/accuracy of diagnosis following review
- Describe clinical consequences of any change in diagnosis identified
- Evaluate utility of AI and greater centralisation pathology reporting

Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

Prioritising Research Wokstreams

3: Exploring patient experiences and developing a core outcome set for decision-making in high-morbidity surgeries.

Context/Challenges:

- Variable clinical decision making for high morbidity/borderline operable cases
- Patient voice is needed
- Need for improved clinical or translational predictors of outcomes

Year 1 deliverables under consideration:

- Qualitative interviews or patient experiences
- Develop core outcome set for studies
- Retrospective analysis of surgical/margin status and outcomes
- Pilot translational studies to develop predictors of outcome

Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

Prioritising Research Wokstreams

4: Analysing diagnostic pathways through a patient survey to identify challenges in primary care and referral practices.

Context/Challenges:

- Most major SGC not referred through gold standard suspected cancer referral pathways
- Current guidance misses important presenting symptoms eg facial palsy
- SGC less likely to be diagnosed at curable stage than other head/neck cancers

Year 1 deliverables under consideration:

- Patient/carer survey of experience of diagnostic pathways
- Focus on salivary type cancers of diverse primary sites
- Stakeholder engagement to review/update/develop guidance documents for submission to NICE

Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

TAKE HOME MESSAGES

The SGC UK RWG is continuing in place of the NCRI to address critical research needs in SGC

Through a series of meetings and online discussions, we identified key areas requiring urgent attention

Initially with a focus on existing guidelines, histopathology accuracy, decision-making processes, and diagnostic pathways, the group aims to improve clinical outcomes for SGC patients

Ongoing collaboration and the development of evidence-based recommendations will guide future research, with a goal to influence clinical practice and policy

ESMO SARCOMA AND RARE CANCERS

Dr Robert Metcalf MB ChB PhD MRCP

TAKE HOME MESSAGES

The top four research questions/workstreams are on a 'rolling' basis with a longer list of 13 RQ's identified for us to address.

International collaboration and inputs are welcomed

You can find more information on our website here:

https://www.salivaryglandcancer.uk/uk-salivary-gland-cancer-research-working-group-uksgcrwg/



Dr Robert Metcalf MB ChB PhD MRCP

2025 ESMO SARCOMA AND RARE CANCERS

Annual Congress

European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org

esmo.org

